Loading...
Please wait, while we are loading the content...
Similar Documents
Resistance to cancer immunotherapy in metastatic renal cell carcinoma.
| Content Provider | Europe PMC |
|---|---|
| Author | Moreira, Marco Pobel, Cedric Epaillard, Nicolas Simonaggio, Audrey Oudard, Stéphane Vano, Yann-Alexandre |
| Abstract | The prognosis of metastatic clear cell renal cell carcinoma (mccRCC) has changed dramatically over the years with the emergence of immune checkpoint inhibitors (ICI) used alone, or in combination with another ICI, or with vascular endothelial growth factor receptor tyrosine kinase inhibitor. Although major response rates have been observed with ICI, many patients do not respond, reflecting primary resistance, and durable responses remain exceptional, reflecting secondary resistance. Factors contributing to primary and acquired resistance are manifold, including patient-intrinsic factors, tumor cell-intrinsic factors and factors associated with the tumoral microenvironment (TME). While some mechanisms of resistance are common to several tumor types, others are specific to mccRCC. Predictive biomarkers and alternative strategies are needed to overcome this resistance. This review provides an overview of the major ICI resistance mechanisms, highlights the potential of the TME to induce resistance to ICI, and discusses the predictive biomarkers available to guide therapeutic choice. |
| Related Links | https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC8992500&blobtype=pdf |
| Journal | Cancer Drug Resistance [Cancer Drug Resist] |
| Volume Number | 3 |
| DOI | 10.20517/cdr.2020.16 |
| PubMed Central reference number | PMC8992500 |
| Issue Number | 3 |
| PubMed reference number | 35582435 |
| e-ISSN | 2578532X |
| Language | English |
| Publisher | OAE Publishing Inc. |
| Publisher Date | 2020-07-02 |
| Access Restriction | Open |
| Rights License | © The Author(s) 2020. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. © The Author(s) 2020. |
| Subject Keyword | Tumor microenvironment clear cell renal cell carcinoma immune checkpoint inhibitor immune checkpoint inhibitor resistance |
| Content Type | Text |
| Resource Type | Article |
| Subject | Pharmacology (medical) Cancer Research |
